ACRV compared with ABOS: revenue, margins and what each company keeps, and the suppliers and customers both name

ACRVAcrivon Therapeutics, Inc.

Mkt capRevenueRevenue

ABOSAcumen Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

ACRVAcrivon Therapeutics, Inc.

ABOSAcumen Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Earnings history

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

last 4 reports each · paired by recencyMethod ›

ACRV1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+7.56%—

ABOS2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+14.65%—

Q2 FY26±15.3%▲+1.62%×0.10

= impliedACRV realized, solidABOS realized, hatchedOne scale, both sides: full bar = 16%× = |realized| ÷ impliedSource: market data

ACRVAcrivon Therapeutics, Inc.

1.66▼−0.78%· post 1.72

Mkt cap$12.6M

ABOSAcumen Pharmaceuticals, Inc.

0.22▼−4.95%· post 0.22

ClosedNov 4 '26

Mkt cap$17.0M

Compare

ClosedNov 4 '26

ACRVAcrivon Therapeutics, Inc.

ABOSAcumen Pharmaceuticals, Inc.

1.66▼−0.78%post 1.72

Price

0.22▼−4.95%post 0.22

$12.6M

Mkt cap

$17.0M

ACRV1.66▼−0.78%vsABOS0.22▼−4.95%ClosedNov 4 '26